|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer显示文摘Metastatic colorectal cancer (mCRC) continues to be counted as a major health problem. The introduction of newer cytotoxics, irinotecan and oxaliplatin, has achieved a significant improvement in survival rates. Novel targeted therapies (bevacizumab, and cetux-imab) in combination with most efficient chemotherapy regimens have pushed the median survival beyond the 2-year mark and increased the proportion of patients which could benefit from resection of metastatic lesions. In addition, several studies have proved that the CRC mutation profiles should influence patient selection or stratif ication in prospective trials. KRAS mutational status represents a paradigm for biomarker development in the era of molecular targeted therapies. The present article is an overview of the most important studies in the development of biomarkers for the optimization of anti-epidermal growth factor receptor (anti-EGFR) treatment in mCRC, beyond KRAS mutations, which is a work in progress. The aim will be to identify molecular markers that might be used to select patients with a higher probability of response to anti-EGFR monoclonal antibodies. Overall the accumulating evidence of the molecular biology of CRC has substantially changed the approach to mCRC treatment and has given clinicians more rational options for treating this illness. | Zacharenia Saridaki Vassilis Georgoulias John Souglakos | 2010 | World Journal of Gastroenterology2010，16，10： | 3 |
| 2 | Prognostic and predictive significance of MSI in stages Ⅱ/Ⅲ colon cancer显示文摘In colon cancer,classic disease staging remains the key prognosis and treatment determinant.Although adjuvant chemotherapy has an established role in stageⅢcolon cancer patients,in stageⅡit is still a subject of controversy due to its restriction to a small subgroup of patients with high-risk histopathologic features.Patients with stageⅡtumors form a highly heterogeneous group,with five-year relative overall survival rates ranging from 87.5%(ⅡA)to 58.4%(ⅡC).Identifying those for whom adjuvant chemotherapy would be appropriate and necessary has been challenging,and prognostic markers which could serve in the selection of patients more likely to recur or benefit from adjuvant chemotherapy are eagerly needed.The stronger candidate in this category seems to be microsatellite instability(MSI).The recently reported European Society for Medical Oncology guidelines suggest that MSI should be evaluated in stageⅡcolorectal cancer patients in order to contribute in treatment decisionmaking regarding chemotherapy administration.Thehypothetical predictive role of MSI regarding its response to 5-fluorouracil-based adjuvant chemotherapy has proven a much more difficult issue to address.Almost every possible relation between MSI and chemotherapy outcome has been described in the adjuvant colon cancer setting in the international literature,and the matter is far from being settled.In this current report we critically evaluate the prognostic and predictive impact of MSI status in patients with stageⅡand stageⅢcolon cancer patients. | Zacharenia Saridaki John Souglakos Vassilis Georgoulias | 2014 | World Journal of Gastroenterology2014，20，22： | 3 |
| 3 | Use of site-directed nmtagensis to identify residues specific for each reaction catalyzed by chorismate mutase-prephenate dehydrogenase from Escheriehia coli 显示文摘 | Christendat D Saridakis V C Jurnbull J L | 1998 | Biochemistry1998，37，15： | 1 |
| 4 | Finite element collocation approximation of the characteristic exponent in BVPs with periodic coefficients显示文摘 | Saridakis Y G Sifniotopoulos C G Sotiropoulos D A | 1996 | Journal of Computational and Applied Math-ematics1996，70，： | 1 |
| 5 | Protein crystallization: From purified protein to diffraction-quality crystal 显示文摘 | CHAYEN N E SARIDAKIS E | 2008 | Nat Methods2008，5，： | 1 |
| 6 | A triplet combina- tion with irinotecan (CPT-ll),oxaliplatin (LOHP),continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetux- imab as first-line treatment in KRAS wt,metastatic colorectalcancer: a pilot phase II trial显示文摘 | Saridaki Z Androulakis N Vardakis N | 2012 | Br J Cancer2012，107，12： | 1 |
| 7 | Porous silicon: An effective nucleation-inducing material for protein crystallization显示文摘 | Chayen N E Saridakis E El-Bahar R | 2001 | J Mol Biol2001，312，4： | 1 |
| 8 | Toll-like receptors gene polymorphisms may confer increased susceptibility to breast cancer development 显示文摘 | Theodoropoulos George E Saridakis Vasilios Karantanos Theodoros | 2012 | Breast2012，21，4： | 1 |
| 9 | Experiment and theory for heterogeneous nucleation of protein crystals in a porous medium显示文摘 | Chayen N E Saridakis E Sear R P | 2006 | Proc Natl Acad Sci USA2006，103，3： | 1 |
| 10 | Treating severe cardiogenic shock by large counterpulsation volumes显示文摘 | Stamatelopoulos S F Nanas J N Saridakis N S | 1996 | Ann Thorac Surg1996，62，4： | 1 |
| 11 | Mutational analysis of CDKN2A genes in patients with squamous cell carcinoma of the skin显示文摘 | Saridaki Z Liloglou T Zafiropoulos A | 2003 | Br J Dermatol2003，148，4： | 1 |
| 12 | Mutational analysis of CDKN2A genes in patients with squamous cell carcinoma of the skin显示文摘 | SARIDAKI Z LILOGLOU T ZAFIROPOULOS A | 2003 | Br J Dermatol2003，148，4： | 1 |
| 13 | Experiment and Theory for Heterogeneous Nucleation of Protein Crystals in a PorousMedium显示文摘 | Chayen N E Saridakis E Sear R P | 2006 | Proc Natl Acad Sci USA2006，103，3： | 1 |
| 14 | Towards a 'universal' nucleant for protein crystallization显示文摘 | Saridakis E Chayen N E | 2009 | Trends Biotechn2009，27，2： | 1 |
| 15 | BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome显示文摘 | Saridaki Z Papadatos-Pastos D Tzardi M | 2010 | Br J Cancer2010，102，12： | 1 |
| 16 | A dose escalation and pharmacokinetic study of the biweekly administration of paclitax- el, gemcitabine and oxaliplatin in patients with advanced solid tumors显示文摘 | Saridaki Z Pappas P Souglakos J | 2009 | Cancer Chemother Pharmacol2009，65，1： | 1 |
| 17 | Phase-space analysis of interacting phantom cosmology 显示文摘 | CHEN X M GONG Y G SARIDAKIS N E | 2009 | JCAP2009，，04： | 1 |
| 18 | Stochastic optimization for a tip-tilt adaptive correcting system 显示文摘 | M S Zakynthinaki Y G Saridakis | 2003 | Computer Physics Communication2003，150，3： | 1 |
| 19 | A let-7 microRNAbinding site polymorphism in kras predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy显示文摘 | Saridaki Z Weidhaas JB Lenz HJ | 2014 | Clin Cancer Res2014，20，： | 1 |
| 20 | Block AOR iterative schemes for large- scale least-squares problems 显示文摘 | Papadopoulou E P Saridakis Y G Papatheodorou T S | 1989 | SIAM Journal on Numerical Analysis1989，26，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员